Article From: "Allison DeAngelis"   Read full article

Cambridge biotech Moderna Therapeutics’ announcement that it would seek up to $600 million in its IPO raised eyebrows. But it’s just be the latest in the biotech industry’s increasingly high-priced market launches.

Moderna is currently testing a dozen treatments using messenger RNA technology, but like many biotech companies that have launched IPOs in recent years, does not yet have any approved drugs.

The IPO — which is expected to launch this week — will likely set records as the highest-ever…